T Wandert
Overview
Explore the profile of T Wandert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atzpodien J, Wandert T, Reitz M
Crit Rev Oncol Hematol
. 2005 Aug;
55(3):193-9.
PMID: 16115777
Purpose: Based on the increasing proportion of elderly cancer patients, we compared the efficacy of subcutaneous cytokine based home therapy in older (age > or = 60 years) and younger...
2.
Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, et al.
Br J Cancer
. 2005 Mar;
92(5):843-6.
PMID: 15756254
We conducted a prospectively randomised clinical trial to investigate the role of adjuvant outpatient immunochemotherapy administered postoperatively in high-risk patients with renal cell carcinoma. In total, 203 renal carcinoma patients'...
3.
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, et al.
J Clin Oncol
. 2004 Feb;
22(7):1188-94.
PMID: 14981107
Purpose: We conducted a prospectively randomized clinical trial to compare the efficacy of three outpatient therapy regimens in 341 patients with progressive metastatic renal cell carcinoma. Patients And Methods: Patients...
4.
Atzpodien J, Kuchler T, Wandert T, Reitz M
Br J Cancer
. 2003 Jul;
89(1):50-4.
PMID: 12838299
We conducted a prospective quality-of-life analysis during outpatient immunotherapy in 22 patients with progressive metastatic renal cell carcinoma (RCC) treated with subcutaneous interferon-alpha2a and subcutaneous interleukin-2. Patients' quality of life...
5.
Atzpodien J, Royston P, Wandert T, Reitz M
Br J Cancer
. 2003 Feb;
88(3):348-53.
PMID: 12569375
The purpose of the study was to identify a comprehensive prognostic system of pretreatment clinical parameters in 425 patients (pts) with metastatic renal-cell carcinoma treated with different subcutaneous (s.c.) recombinant...
6.
Atzpodien J, Kirchner H, Illiger H, Metzner B, Ukena D, Schott H, et al.
Br J Cancer
. 2001 Nov;
85(8):1130-6.
PMID: 11710825
We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-alpha2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients...
7.
Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, et al.
Br J Cancer
. 1999 Mar;
79(7-8):1182-4.
PMID: 10098756
Interleukin 10 (IL-10) is an immunosuppressive factor and has been detected in tumour cell cultures of renal cell carcinoma and of malignant melanoma. IL-10 has been described as a cytokine...